Given our results from analysis of human TMAs that indicate 31% of HER2 positive breast cancers lack LKB1 expression (Table 1, Fig. 1), we investigated whether the loss of LKB1 expression would alter the latency of ErbB2-mediated tumorigenesis. Here, STK11 is linked to breast carcinoma.